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Abstract
Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae that can manifest a wide
variety of immunological and clinical outcomes ranging from potent humoral responses among borderline
lepromatous (BL) and lepromatous (LL) patients to strong cellular responses among tuberculoid (TT) and borderline
tuberculoid (BT) patients. Until recently, relatively little has been known about the immune responses to individual
proteins of M. leprae recognized during leprosy.
Methods: The immune reactivity to a panel of 33 M. leprae recombinant proteins was evaluated among leprosy
patients and controls from a high endemic area for leprosy (Goiania/GO, Central Brazil). Serum IgG responses were
measured by ELISA (45 participants/group) and T cell responses (20 participants/group) were evaluated by IFN-
gamma production in 24 hours whole blood cultures with antigen (whole blood assay-WBA). Study groups were
newly diagnosed, untreated TT/BT and BL/LL leprosy patients classified by Ridley Jopling criteria and household
contacts of BL/LL patients (HHC). Control groups were HIV-1 negative pulmonary tuberculosis patients (TB) and
healthy individuals from the same endemic area (EC). In silico predictions indicated the level of identity of M. leprae
proteins with homologues in other mycobacteria and the presence of T cell and B cell epitopes.
Results: Despite the prediction that all proteins would be reactive, 16 of 33 (48%) of the single proteins tested
were immunogenic (recognized in WBA or ELISA) and seventeen were non-immunogenic (not recognized in either
assay). Among the 16 immunogenic proteins, 9 were considered leprosy specific in WBA inducing cell-mediated
IFN-gamma secretion from TT/BT patients and HHC. Three of these proteins were also leprosy specific in serology
being recognized by serum IgG from LL/BL patients. Seven of the immunogenic proteins were not leprosy specific.
Conclusions: New M. leprae antigens recognized by antibody responses of BL/LL patients and cellular responses of
TT/BT leprosy patients were identified. An improved serological diagnostic test for leprosy could be developed by
incorporating these IgG-reactive antigens to the current PGL-I based tests. Moreover our data indicate that the
WBA is a robust, relatively simple and user friendly format for a T cell based diagnostic test. The field use of these
test formats in leprosy endemic countries could contribute to early leprosy diagnosis before the development of
deformities and disabilities.
Background
Leprosy, caused by infection with Mycobacterium leprae,
is one of the oldest known human infectious diseases and
remains an important public health problem for many
countries, including Brazil [1]. M. leprae infects macro-
phages and Schwann cells, causing peripheral nerve
damage which results in sensory and motor loss that ulti-
mately cause the severe disability that is a hallmark of
leprosy [2]. Leprosy actually manifests across a bacteriolo-
gic, clinical, immunologic and pathologic spectrum that
allows classification into five forms according to the Rid-
ley-Jopling scale. Weak antibody responses and strong
cell-mediated immunity (CMI) classically characterize the
immune response of tuberculoid (TT) and borderline
tuberculoid (BT) patients who have a low bacterial burden.
In contrast, strong antibody responses and weak CMI
are classically observed in borderline borderline (BB),
* Correspondence: mstefani@iptsp.ufg.br
1Tropical Pathology and Public Health Institute, Federal University of Goiás,
Rua 235 esquina com 1a Avenida, Setor Universitário, sala 335, Goiânia, GO,
74605050, Brazil
Full list of author information is available at the end of the article
Sampaio et al. BMC Infectious Diseases 2011, 11:26
http://www.biomedcentral.com/1471-2334/11/26
© 2011 Sampaio et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.borderline lepromatous (BL) and lepromatous (LL) cases
that have a high bacterial burden and are believed to
transmit M. leprae infection [3-5].
Seeking to eliminate leprosy by the year 2000, a cam-
paign by the World Health Organization was based on
widespread provision and use of multidrug therapy
(MDT) to control infection and reduce transmission.
This campaign has produced a large decline in global
prevalence of leprosy over the last 20 years, but despite
this, the new case detection rate is still high in many
regions [1]. The diagnosis of leprosy remains based on
the appearance of clinically relevant manifestations and
treatment has been simplified to incorporate recom-
mended MDT regimen of 6 months for paucibacillary
patients (PB; encompassing TT and BT forms) and of
12 months for multibacillary patients (MB; encompassing
LL, BL, BB and some BT forms). Unfortunately, the scar-
city of early signs or symptoms, as well as the problem
that leprosy symptoms may be confused with other dis-
eases, often leads to significant delays in proper diagnosis
and appropriate treatment [6]. A further compounding
factor is the reduction in the number of clinicians with
expertise at identifying leprosy that has occurred along-
side the reduction in case numbers [7]. Early leprosy
diagnosis, to promote even earlier treatment, is regarded
as critical to provide further reductions in transmission
and decrease the number of patients presenting with dis-
abilities [8,9]. To date, simple, rapid tests have been
developed to diagnose MB leprosy but tests for PB
leprosy are not yet available [10,11].
As with other diseases, rapid and objective diagnosis
of leprosy could be achieved by the recognition of dis-
ease-specific immune responses [8]. Due to the dichoto-
mous nature of immune responses of leprosy patients,
diagnostic tests for all leprosy forms would probably
require antigens that are targets of both antibody and
cellular responses [8,12]. The identification of T cell-
reactive antigens may also reveal proteins that are part
o ft h ep r o t e c t i v er e s p o n s ea g a i n s tl e p r o s yt h a ta r e
worthy of further examination in the context of vaccine
development. The selection and production of proteins
for immune evaluation has been expedited by recent
advances such as the sequencing of the M. leprae gen-
ome and could be further simplified when coupled with
effective in silico epitope predictions [13-18]. Most stu-
dies investigating the reactivity of M. leprae antigens
have described either the antibody or T cell reactivity
among leprosy patients but have not typically compared
these responses in parallel [4,9,19-26]. The current
study was designed to explore the immune reactivity of
a panel of 33 M. leprae recombinant proteins among
leprosy patients and to concomitantly evaluate the utility
of computational softwares to predict this reactivity.
This study identified several antigens that are targets of
the cellular response and some that are targets of the
antibody response. Moreover it indicated that the bene-
fits of current computational predictions of immune
reactivity were limited.
Methods
Study participants
This study was approved by local (Comitê de Ética em
Pesquisa Humana e Animal do Hospital das Clínicas da
Universidade Federal de Goias) and National Ethics
Commission (Comissão Nacional de Ética Pesquisa/
CONEP/Brazil protocols #4862 and #12962). Newly
diagnosed, previously untreated leprosy patients were
recruited between November 2006 and January 2009 at
a main outpatient clinic (Centro de Referência em Diag-
nóstico e Terapêutica) in Goiânia, Goiás State, in Cen-
tral-West Brazil. Before recruitment all patients were
provided complete dermato-neurological evaluations by
a dermatologist with expertise in leprosy diagnosis. Par-
ticipants were included only after signing written
informed consent forms. Patients were assigned to
leprosy groups based upon their immediate diagnosis,
and were subsequently thoroughly characterized accord-
ing to Ridley-Jopling criteria, taking into account clini-
cal, bacilloscopic and histopathological findings [27]. All
patients assigned to the TT/BT group had negative
bacilloscopic index (BI), whereas LL/BL cases were BI
positive. Tuberculosis patients (TB), healthy household
contacts of LL/BL patients (HHC) and healthy endemic
controls (EC) from the same endemic region were
included as control groups. TB patients were HIV-
negative individuals with clinically confirmed pulmonary
tuberculosis (Mycobacterium tuberculosis sputum-
positive) in their final 3 months of chemotherapy. HHC
were adults living in the same house as a multibacillary
index case for at least 6 months prior to study enroll-
ment and blood collection. EC were healthy individuals
recruited among non leprosy patients at a public health
center from the same endemic setting. EC had neither
tuberculosis nor history of leprosy in their families. All
study participants had a BCG scar, consistent with the
neonatal BCG vaccination coverage close to 100% in
this recruitment setting. All study participants came
from Goias State, an endemic region for leprosy (preva-
lence rate = 6.02 patients/10000 inhabitants). The serol-
ogy study included 45 participants per group and the T
cell study included 20 participants per group and results
from these separate studies were combined in this
manuscript. The fine composition of each study group
is summarized in Table 1.
Antigens
Thirty-three M. leprae recombinant proteins were evalu-
ated for immune reactivity (ML0022, ML0051, ML0098,
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ML0540, ML0810, ML0811, ML0840, ML1383, ML1556,
ML1632, ML1181, ML1481, ML1633, ML1685, ML2028,
ML2044, ML2055, ML2203, ML2331, ML2346, ML2358,
ML2380, ML2541, ML2603, ML2629, ML2655 and
ML2659). Proteins were selected either from previous
M. leprae cDNA library screening results [28] or on the
basis of homology with known secreted M. tuberculosis
proteins. Cloning and purification from E. coli were per-
formed as previously described [4,28]. Endotoxin levels
for each protein were <100 EU/mg protein, as measured
by Limulus Amebocyte Lysate QCL-1000 assay (Lonza
Inc., Basel, Switzerland). Details for selected M. leprae
recombinant proteins are provided in Table 2.
CMI determination by whole blood assay (WBA)
WBA was performed as previously described [4]. Briefly,
at the time of initial diagnosis and operational assign-
ment to MB or PB groups, prior to full characterization
by Ridley-Jopling, undiluted heparinized venous whole
blood (Greiner) was collected. Whole blood was plated
into 24-well plates (450 μl/well; Sigma, St. Louis, MO)
within 2 hours of collection and incubated with stimu-
lants for 24 hours at 37°C 5% CO2. Each assay included
stimulation with 10 μg/ml of individual M. leprae
recombinant protein for experimental evaluations, and
with PBS alone, 10 μg/ml M. leprae cell sonicate
(MLCS; provided by Dr. John Spencer, Colorado State
University, Fort Collins, CO under NIH contract N01
AI-25469) or 1 μg/ml PHA (Sigma) as controls (Addi-
tional File 1). Approximately 150 μlp l a s m aw e r ec o l -
lected and stored at -20°C until IFNg determination.
IFNg concentration was determined by ELISA, according
to the manufacturer’s instructions (eBioscience kit, San
Diego, CA). The IFNg ELISA employed had a detection
limit of 20 pg/ml and an arbitrary cut-off point of
50 pg/ml was used to determine positive responses.
Antibody ELISA to M. leprae recombinant proteins
Serum IgG antibodies were determined by ELISA as pre-
viously described [3]. Polysorp 96-well plates (Nunc,
Rochester, NY) were coated with 2 μg/ml recombinant
protein at 4°C and blocked with PBS/Tween-20 with 1%
(wt/vol) BSA. Serum samples diluted 1/200 in 0.1% BSA
were added and incubated for 1 hour at RT. Plates were
washed and incubated with horseradish peroxidase-
conjugated anti-human IgG (Southern Biotech, Birming-
ham, AL). After washing, reactions were developed with
peroxidase color substrate (KPL, Gaithersburg, MD), and
quenched by the addition of 1N H2SO4. The corrected
optical density of each well at 450 nm was read using a
VERSAmax microplate reader (Molecular Devices, Orleans
Drive Sunnyvale, CA). Responses were defined as positive
if the median was above the arbitrary cut-off (OD >0.3).
ELISA to PGL-I antigen
IgM antibodies to M. leprae cell wall phenolic glycolipid
I (PGL-I) were detected as described [3]. Briefly 200 ng/
ml of natural disaccharide with octyl linkage (NDO)
conjugated to bovine serum albumin (NDO-BSA; kindly
supplied by John Spencer, Colorado State University,
under NIH contract N01 AI-25469) was used. Serum
samples diluted 1/300 in 0.1% BSA were tested in dupli-
cates. After incubation and washings horseradish peroxi-
dase-conjugated to anti human IgM (Rockland
Immunochemicals, Gilbertsville, PA) was added and
incubated. After washings peroxidase color substrate
(KPL, Gaithersburg, MD) was added and the reaction
was quenched by the addition of 1 N H2SO4. The opti-
cal density (OD) was read at 450 nm. Positive responses
were defined as an OD of 2x the mean OD of healthy
endemic controls. Results of IgM anti PGL-I serology in
each study group are shown in Table 1.
Comparative genomics and epitope predictions
The amino acid sequences of the M. leprae proteins evalu-
ated in this study were obtained from the Leproma
website (available at http://genolist.pasteur.fr/Leproma/)
and the SANGER CDS Retrieve Information (available at
http://www.sanger.ac.uk/cgi-bin/yeastpub/get_cds?orga
nism=M_leprae) [14,16]. The percentage of amino acid
identity of each M. leprae protein tested was assessed
against homologues in other mycobacteria that were
revealed by the comparative protein analyses based on
complete proteome databases from other mycobacteria
that have the potential to infect humans: M. tuberculosis,
Table 1 Main characteristics of study groups and anti PGL-I serology data.
Group Sex ratio (m/f) Mean age (years, range) BI (mean, range) PGL-I serology mean OD (range)
PB (29 TT/36 BT) 31/34 33 (18-76) 0 (0) 0,19 (0 - 1,03)
MB (23 BL/42 LL) 37/28 51 (18-100) 3.75 (0.5-6.0) 0,82 (0,08 - 2,76)
HHC 32/33 36 (19-60) na 0,09 (0 - 0,53)
TB 39/26 38 (20-67) na 0,07 (0 - 0,30)
EC 32/33 35 (18-58) na 0,07 (0,01 - 0,30)
PB: paucibacillary leprosy consisting of TT and BT forms; MB: multibacillary leprosy consisting of BL and LL forms; m/f: male/female ratio; BI- bacilloscopic index;
Optical density (OD) of IgM antibodies to PGL-I antigen detected by ELISA; na: not applicable.
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bacterium marinum, Mycobacterium ulcerans, Mycobac-
terium bovis BCG, Mycobacterium paratuberculosis
and Mycobacterium microti. BLAST UniProt (The Univer-
sal Protein Resource) database (available at http://www.
uniprot.org) was used to compare a given amino acid
sequence with sequences of other proteins from the NCBI
database indicating sequences with identity above 30%
[15,29]. The potential of the selected M. leprae proteins to
present promiscuous MHC class II T cell epitopes was
predicted by PROPRED server (available at http://www.
imtech.res.in/raghava/propred/) which uses a panel of 51
different HLA-DR alleles (HLA-DRB1 and HLA-DRB5)
[13,30]. The prediction of B cell epitopes containing 16
amino acids in the selected M. leprae proteins was
attained using the artificial neural network based server
ABCpred (available at http://www.imtech.res.in/raghava/
abcpred/ABC_submission.html) [17,31].
Statistical analysis
Exploratory data analysis, including box-plots and scat-
ter plots, medians and interquartile range (IQR) were
used to analyze the IFNg levels and OD of IgG reactivity
among different study and control groups. Proteins that
Table 2 Representative M. leprae recombinant antigens examined by comparative genomics and actual immune
responses.
% Amino acid identity and orthologous genes
1 Number
of
Predicted
epitopes
2
Immunogenicity
specificity
3
Gene Predicted Function Size
(aa)
M.
ulcerans
M. avium M. bovis
(BCG)
M. marinum M.
tuberculosis
T
cell
B
cell
WBA IFNg Ab
ML0405 hypothetical protein 394 29
(MUL_5045)
-6 2
(BCG_3680c)
57
(MMAR_4515)
62
(Rv3616c)
7 39 +/+ +/+
ML2331 possible secreted protein 256 81
(MUL_4308)
80
(MAV_0385)
82
(BCG_3777)
81
(MMAR_5233)
81 (Rv3717) 4 24 +/+ +/+
ML2055 fibronectin attachment
protein
287 65
(MUL_3017)
57
(MAV_2859)
67
(BCG_1896)
65
(MMAR_2737)
67(Rv1860) 6 15 +/+ +/+
ML1685 3-isopropylmalate
dehydratase
476 86
(MUL_1968)
88
(MAV_3838)
88
(BCG_3009c)
88
(MMAR_1726)
88
(Rv2988c)
3 25 +/+ -
ML1632 possible hydrolase 511 73
(MUL_1334)
77
(MAV_2243)
75
(BCG_2040c)
74
(MMAR_3295)
75
(Rv2223c)
4 32 +/+ -
ML1556 initiation factor IF-2 924 83
(MUL_2122)
81
(MAV_3693)
83
(BCG_2859c)
82
(MMAR_1894)
83
(Rv2839c)
3 17 +/+ -
ML2044 Possible glycosyl hydrolase
(pseudogene)
73 - - - - - 3 7 +/+ -
ML0840 hypothetical protein 434 - 66
(MAV_2053)
- - - 3 22 +/+ -
ML0276 hypothetical protein 147 - 71
(MAV_4774)
78
(BCG_0427)
70
(MMAR_0687)
78 (Rv0390) 5 14 +/+ +/-
ML2541 acyl-CoA synthase
(pseudogene)
146 77
(MUL_0004)
78
(MAV_0004)
83
(BCG_0004)
78
(MMAR_0004)
77 (Rv0004) 5 15 +/- -
ML2203 hypothetical protein 373 76
(MUL_0420)
76
(MAV_0750)
77
(BCG_0863c)
75
(MMAR_4878)
77
(Rv0811c)
6 17 +/- -
ML2358 probable acyl-CoA synthase 583 77
(MUL_2020)
56
(MAV_1328)
77
(BCG_2952)
77
(MMAR_1777)
76 (Rv2930), 3 15 +/- -
ML2346 hypothetical protein 301 - - - - - 5 12 +/- -
ML2380 possible secreted protein 153 65
(MUL_1413)
66
(MAV_4695)
66
(BCG_0494c)
65
(MMAR_0777)
66
(Rv0455c)
3 15 +/- -
ML2603 possible lysophospholipase 279 73
(MUL_1077)
77
(MAV_4997)
74
(BCG_0220)
74
(MMAR_0427)
74 (Rv0183) 5 16 +/- -
ML0022 hypothetical protein 488 71
(MUL_0024)
66
(MAV_0024)
72
(BCG_0050c)
69
(MMAR_0022)
72 (Rv0020) 5 17 +/- -
1 Blast Search for amino acid identity was performed using BLAST Uniprot (http://www.uniprot.org/). (-) = no homologue found. Locus_tag othologous genes are
indicated within parentheses.
2 Promiscuous T cell epitopes predicted to be recognized by least 26 of 51 different HLA-DR alleles identified by PROPED server (http://www.imtech.res.in/
raghava/propred/), and the number of potential B cell epitopes predicted by ABCpred server (http://www.imtech.res.in/raghava/abcpred/ABC_submission.html).
3Immu/spec = immunogenicity/specificity; WBA +/+ = immunogenic protein that gives specific cellular response; WBA +/- = immunogenic protein that gives
unspecific cellular response; Ab +/+: immunogenic protein that induces specific antibody response; Ab+/-: immunogenic protein that induces unspecific antibody
response. (-) = not immunogenic.
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>0.3 for IgG ELISA or IFNg secretion >50 pg/ml in
WBA) were classified as “immunogenic”. For T cell
recognition M. leprae-specificity was defined according
to reactivity of proteins among TT/BT leprosy patients
and at risk HHC, and lack of reactivity among TB and
EC groups. For serology M. leprae specific proteins were
recognized by IgG antibodies from leprosy patients
especially BL/LL categories and by lack of recognition
by HHC, EC and TB groups. Statistical significance was
assessed by Kruskall-Wallis one way analysis of variance
for comparison of multiple groups and Mann-Whitney
for comparison between two groups. Results were con-
sidered statistically significant when p-values < 0.05
were obtained.
Results
ML0405, ML2055 and ML2331 proteins elicit leprosy-
specific cellular and humoral responses
Dependent upon their disease presentation, leprosy
patients can be characterized as having strong antibody
responses (MB; LL/BL) or strong cellular responses (PB;
TT/BT) against crude M. leprae antigens. It is unclear if
these different patient groups respond to the same or
different individual antigens. To address this question,
we compared the antigen-specific immune response of
leprosy patients and controls. When incubated with
blood from TT/BT and HHC groups, the ML0405,
ML2055 and ML2331 proteins induced strong IFNg pro-
duction (Figure 1). The ML0405 and ML2055 antigens
each induced secretion of IFNg greater than 50 pg/ml in
95% (19 of 20) of TT/BT leprosy patients examined. The
ML2331 antigen induced response greater than 50 pg/ml
IFNg in 85% (17 of 20) of the TT/BT cases examined.
The ML0405 and ML2331 proteins also induced produc-
tion of IFNg levels above the 50 pg/ml cut-off among
80% HHC (16 of 20 cases to each antigen), consistent
with this group being exposed to M. leprae. The ML2055
antigen similarly induced secretion of IFNg greater than
50 pg/ml in 75% HHC (15 of 20 cases). In contrast, with
the exception of one LL/BL patient responding to
ML0405 and one EC responding to ML2055, IFNg
responses above 50 pg/ml were not observed in the
LL/BL leprosy or control groups (Figure 1).
Although not recognized in terms of IFNg production
within WBA with LL/BL blood, as we previously
reported, the ML0405 and ML2331 proteins were well
recognized by serum IgG from LL/BL leprosy group
Figure 1 Identification of leprosy-specific antigens by cellular and antibody responses. WBA-IFNg secretion and serum IgG responses were
determined for ML0405, ML2331 and ML2055. For WBA blood from leprosy patients and controls were incubated for 24 h with ML0405, ML2331
and ML2055 antigens, and IFNg secretion determined by ELISA. The dotted lines represent the arbitrary cut-off IFNg above 50 pg/ml. WBA results
are presented as box plots encompassing the 25th and 75th percentiles, and the black line within each box indicating the median value, n = 20
per group. IgG ELISA data are shown in scatter plots of individual values for each individual serum tested, n = 45 per group. The dotted line
indicates the calculated cut-off for positive responses (OD >0.3).
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Page 5 of 11(Figure1) [3,28]. The ML2055 antigen demonstrated a
strong serum antibody reactivity in the LL/BL patient
group (median OD = 1.43; IQR = 1.26) with 58% (26 of
45) sera binding above the positive threshold (OD >0.3;
Figure 1). Antibody responses to ML0405, ML2055 and
ML2331 within all other groups analyzed (TT/BT,
HHC, TB and EC) were weak or absent. Taken together,
the data indicate that ML0405, ML2055 and ML2331
are recognized specifically among leprosy patients and
contacts, albeit differentially inducing either antibody or
cellular responses.
Antigens that stimulate leprosy-specific CMI without
specific antibody responses
Five proteins were found to elicit cellular responses
despite not being detected by serum antibodies. In
agreement with our previous findings, antigens ML0840
and ML2044 induced significantly greater IFNg secre-
tion in WBA using blood from TT/BT leprosy patients
than WBA using EC blood (Figure 2) [4]. These pro-
teins did not, however, demonstrate significant antibody
reactivity in any of the study groups (Figure 2). Among
the TT/BT patients, IFNg production was induced by
incubation with the ML1632 protein in 80% (16 of 20)
cases; by the ML1685 and ML1556 proteins in 75% (15
of 20) cases. Antigen-specific IFNg responses were again
induced in the HHC samples, with 65% HHC (13 of 20)
responding to the ML1632 and ML1685 proteins, and
25% HHC (5 of 20) responding to the ML1556 protein
(Figure 2). Thus, our data identifies five M. leprae pro-
teins (ML0840, ML2044, ML1632, ML1685 and
ML1556) that, despite stimulating IFNg production in
WBA using blood from the TT/BT and HHC groups,
are not detected by serum IgG responses of leprosy
patients.
We previously demonstrated that the ML0276 protein
induces IFNg secretion from TT/BT leprosy patient and
HHC blood but not from controls [4]. When the
ML0276 protein was used in ELISA to detect antibodies,
strong serum IgG reactivity was observed in all study
groups (Figure 3). Our data thereby indicate that
although the cellular response to ML0276 is specific to
leprosy groups, the anti-ML0276 antibody response
lacks specificity. Medium values of IFNg produced in
WBA and OD of ELISA tests to detect IgG to the
immunogenic M. leprae recombinant proteins identified
in this study, stratified by different study groups are
shown in Additional File 2.
Non-specific cellular responses are observed against
many proteins
In contrast with the leprosy-specific cellular responses of
the proteins categorized above, several of the recombi-
nant proteins tested, in addition to the TT/BT leprosy
group, stimulated IFNg release in the TB or EC groups
(ML0022, ML2358, ML2346, ML2380, ML2541,
ML2603 and ML2203) (Figure 4). Of note, the LL/BL
leprosy group did not respond to these proteins. The
number of responders to each of these proteins, and the
magnitude of the response, were generally also much
lower than those observed for the proteins that were
specifically recognized by TT/BT leprosy group. Despite
the presence of cellular responses, these proteins did
not demonstrate IgG reactivity.
Figure 2 Proteins that are specifically recognized by cellular responses do not necessarily elicit serum antibodies. WBA-IFNg secretion
and serum IgG responses were assessed against the ML1632, ML1685, ML1556, ML2044 and ML0840 proteins. WBA results are presented as box
plots encompassing the 25th and 75th percentiles, and the black line within each box indicating the median value, n = 20 per group. Antibody
results are shown in scatter plots of individual values for each individual serum tested, n = 45 per group. The dotted line indicates the calculated
cut-off for positive responses (OD >0.3).
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WBA-IFNg and serum IgG responses against ML0276 are shown as an example of a protein specific for WBA IFNg but that lacks specificity for
serum IgG responses. WBA results are presented as box and whisker plots, with the boxes encompassing the 25th and 75th percentiles, and the
black line within each box indicating the median value, n = 20 per group. Antibody results are shown in scatter plots of individual values for
each individual serum tested, n = 45 per group. The dotted line indicates the calculated cut-off for positive responses (OD >0.3).
Figure 4 M. leprae proteins that lack specificity. The proteins ML0022, ML2358, ML2346, ML2380, ML2541, ML2603 and ML2203 were
immunogenic but not specific. WBA results are presented as box and whisker plots, with the boxes encompassing the 25th and 75th
percentiles, and the black line within each box indicating the median value, n = 20 per group. Antibody results are shown in scatter plots of
individual values for each individual serum tested, n = 45 per group. The dotted line indicates the calculated cut-off for positive responses (OD
>0.3).
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are poor
Comparative analyses of amino acid sequences of the M.
leprae proteins evaluated immunologically were con-
ducted against the predicted proteomes of M. tuberculo-
sis, M. avium, M. marinum, M. ulcerans, M. bovis BCG
(Table 2), M. smegmatis, M. paratuberculosis and M.
microti (Additional File 3). Only the ML2346 protein
could be considered M. leprae unique, with no homolo-
gues found in the other mycobacteria species examined
(Table 2). The other M. leprae proteins tested herein
possessed an ortholog protein in other pathogenic
mycobacteria, with homology ranging from 29% to 97%
(Table 2 and Additional File 3). This high homology
was not, however, associated with a lack of specificity in
ex vivo assays. For example, the ML2331 protein pos-
sesses 81% homology with the Rv3717 ortholog in M.
tuberculosis, but this protein was not reactive with TB
patient samples and responses against ML2331 could
only be demonstrated in leprosy patients (or HHC).
Thus, despite possessing significant levels of homology
with other mycobacteria species, several M. leprae pro-
teins are only recognized in the context of leprosy.
Having found widely discrepant levels of reactivity in
our immune assays, we retrospectively compared our
results with in silico predictions to determine if compu-
tational analyses could have streamlined the in vivo
assays. In general, the number of predicted B cell and T
cell epitopes was directly proportional to the size of the
protein (Table 2). In silico predictions indicated that
each of the proteins tested contained up to seven pro-
miscuous T cell epitopes, indicating that all had the
potential to be reactive in WBA (Table 2). This predic-
tion clearly contradicts our observation that more than
half of the antigens tested (ML0051, ML0098, ML2028,
ML0176, ML1633, ML0393, ML0489, ML2655, ML0491,
ML0540, ML0810, ML1383, ML1481, ML2629, ML2659,
ML0811 and ML1181) neither induced IFNg secretion
nor showed IgG reactivity (Figure 5). The in silico pre-
dictions of HLA binding regions within an antigen
sequence do not predict interactions with the T cell
receptor (TCR). The analyses employed herein were
poor to determine the proteins that are targets of the
adaptive immune response of leprosy patients.
Discussion
Early and accurate diagnosis of leprosy and MDT are
considered essential to disrupt M. leprae transmission
and leprosy incidence. Due to the complex and varying
immune responses that characterize leprosy spectrum, it
is likely that immune diagnosis will only be achieved by
antigens that specifically induce cellular and humoral
responses [8,19]. Identifying antigens that are targets of
the proinflammatory T cell response could also reveal
those that are associated with limiting M. leprae burden
and therefore useful for vaccination. In this study a
panel of recombinant M. leprae proteins was evaluated
for the ability to induce CMI and antibody responses to
identify antigens that are specifically reactive in leprosy
patients. Although many antigens were identified as cel-
lular targets by their ability to induce IFNg secretion in
WBA of TT/BT leprosy patients and HHC, a minority
of the screened proteins induced serum IgG responses
in BL/LL patients, such that few proteins induced speci-
fic responses across the leprosy spectrum.
In silico analysis predicted the presence of T cell and
B cell epitopes within all of the M. leprae proteins tested
in this study. The most promiscuous T cell epitope pre-
dicted was located in ML0405 protein, which was esti-
mated to contain T cell epitopes recognized by 50 of 51
of HLA-DR alleles along with 24 potential B cell epi-
topes. Consistent with this prediction, the ML0405 pro-
tein was recognized by IFNg release in WBA using TT/
BT leprosy patient blood and by serum IgG from LL/BL
leprosy patients. However, despite the prediction that all
of the evaluated proteins would possess multiple HLA-
DR epitopes, more than half (17 of 33; 52%) of the pro-
teins were not recognized by leprosy patients or con-
trols. Our results are in agreement with previous studies
that found some of these proteins were not immuno-
genic [4,9,19-25]. Although we cannot exclude the possi-
bility that the proteins investigated were not recognized
because individuals with the appropriate HLA were not
recruited, we consider this improbable given the large
degree of promiscuity that was predicted. Several other
possibilities could explain the lack of reactivity.
Although we consider it unlikely given the recognition
of positive responses to many proteins, the simplest
explanation would be that recombinant expression in E.
coli leads to significantly different folding and proces-
sing of proteins than occurs during native expression in
M. leprae. A more likely possibility is that these pro-
teins, although present in the genome of M. leprae,m a y
not be translated [16]. Another explanation could be
that limited antigen-presentation or T cell suppression
may occur during leprosy in order to prevent nerve
damage via T cell-mediated killing of M. leprae-infected
Schwann cells. We are aware that the softwares
employed in this study identify and predict HLA binding
regions from antigen sequences without predicting
interactions with the TCR. Therefore the use of other in
silico prediction softwares that also include the probabil-
ity of the antigen being processed, presented in the con-
text of a certain HLA allele and recognized by TCR
could lead to different conlusions.
In leprosy endemic regions the high rates of concomitant
exposure to M. tuberculosis and to other non-pathogenic
environmental mycobacteria could confound the
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Several of the M. leprae antigens tested in this study have
homologues in other mycobacteria with greater than 50%
identity (Table 1). The routine M. bovis BCG vaccination
of newborns in leprosy-endemic countries such as Brazil
could stimulate responses that could cross-react with M.
leprae. M. bovis BCG showed high homology with immu-
nogenic M. leprae proteins (from 62 to 88%) This high
homology was not, however, associated with neither cross
-reactivity nor with a lack of specificity. For example, the
ML2331 protein possesses over 80% identity with M.
tuberculosis and M. bovis BCG proteins but serological and
cellular responses to this antigen were highly specific to
leprosy patients (or at-risk contacts). Antigen expression
levels and bioavailability may determine the immune domi-
nant antigens of each mycobacterial infection, such that
differing responses to similar proteins may distinguish each
disease. As a further demonstration of the limited ability of
in silico predictions to indicate specificity, despite having
no identified homologue in M. tuberculosis,t h eM L 2 3 4 6
protein induced strong IFNg responses in all of the study
groups, including TB patients. Based on these findings we
suggest that, at present, in silico identification of M. leprae
proteins with high identity to other mycobacterial proteins
should not be used as a definitive criterion to exclude
them from further diagnostic or vaccine evaluations.
Several studies have reported antigen-specific cellular
and antibody responses during leprosy, but few studies
have consolidated data to determine if particular antigens
are differentially recognized across the disease spectrum
[3,4,9,19-25]. Araoz et al. described M. leprae recombinant
proteins recognized by antibodies produced by leproma-
tous patients that that could also induce CMI among
tuberculoid patients [19]. Some of the proteins analyzed in
our study (ML1632, ML1685 and ML1556) induced strong
and specific production of IFNg in TT/BT and HHC
groups, demonstrating their potential application for iden-
tification of those at risk of developing tuberculoid leprosy.
These proteins were not, however, recognized by antibo-
dies from LL/BL patients. Our parallel screening suggested
Figure 5 M. leprae proteins that are not reactive in WBA or antibody ELISA. WBA-IFNg secretion and serum IgG responses were assessed
against the proteins ML0051, ML0098, ML2028, ML0176, ML1633, ML0393, ML0489, ML2655, ML0491, ML0540, ML0810, ML1383, ML1481, ML2629,
ML2659, ML0811 and ML1181. WBA results are presented as box and whisker plots, with the boxes encompassing the 25th and 75th percentiles,
and the black line within each box indicating the median value, n = 20 per group. Antibody results are shown in scatter plots of individual
values for each individual serum tested, n = 45 per group. The dotted line indicates the calculated cut-off for positive responses (OD >0.3).
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teins was dependent upon their ability to induce cellular
responses, and indicates only a limited number of M.
leprae antigens contained T cell and B cell epitopes that
are immune reactive in the context of disease (ML0405,
ML2055 and ML2331). These antigens could be consid-
ered priority diagnostic antigens. In order to optimize the
screening of new M. leprae antigens for leprosy diagnosis,
our data suggest that it may be beneficial to conduct WBA
testing before serological assays. If the protein is not able
to induce a T cell response it could be de-prioritized from
further testing.
Conclusions
In summary, our results identify new M. leprae antigens
that are recognized by antibody responses of leproma-
tous patients and cellular responses of tuberculoid
leprosy patients. The identification of IgG-reactive anti-
gens indicates the possibility of developing an improved
serological diagnostic test for leprosy, especially if these
antigens can be incorporated to supplement the current
PGL-I based tests [10,11]. For the diagnosis of tubercu-
loid leprosy, our data indicate the WBA is a robust, rela-
tively simple and user friendly format with which to
screen and identify new diagnostic antigens. Together,
these test formats would be desirable for field use in
leprosy endemic countries and could contribute to the
active detection of leprosy cases before the development
of deformities and disabilities.
Additional material
Additional file 1: IFNg production in WBA upon stimulation with
PHA, MLCwA and PBS. This figure indicates IFNg production upon
stimulation with positive controls (PHA and MLCwA) and the baseline
concentration without any stimulant (PBS alone) used as negative
control.
Additional file 2: IFNg produced in WBA and OD of ELISA tests to
detect IgG to Immunogenic M. leprae recombinant proteins. The
medium values of IFNg and IgG ELISA optical density (OD) are shown in
all study groups.
Additional file 3: Percentage of amino acid identity of
immunogenic M. leprae proteins with proteins from other relevant
mycobacteria species. Blast Search for amino acid identity was
performed using BLAST Uniprot (http://www.uniprot.org/). (-) = no
homologue found. Locus_tag orthologous genes are indicated within
parentheses.
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